| |  Online-Ressource |
|---|
| Verfasst von: | Regierer, Anne C. [VerfasserIn]  |
|---|
| | Hasseli, Rebecca [VerfasserIn] |
|---|
| | Schäfer, Martin [VerfasserIn] |
|---|
| | Hoyer, Bimba F. [VerfasserIn] |
|---|
| | Krause, Andreas [VerfasserIn] |
|---|
| | Lorenz, Hanns-Martin [VerfasserIn] |
|---|
| | Pfeil, Alexander [VerfasserIn] |
|---|
| | Richter, Jutta [VerfasserIn] |
|---|
| | Schmeiser, Tim [VerfasserIn] |
|---|
| | Schulze-Koops, Hendrik [VerfasserIn] |
|---|
| | Strangfeld, Anja [VerfasserIn] |
|---|
| | Voll, Reinhard E. [VerfasserIn] |
|---|
| | Specker, Christof [VerfasserIn] |
|---|
| | Mueller-Ladner, Ulf [VerfasserIn] |
|---|
| Titel: | TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD |
|---|
| Verf.angabe: | Anne Constanze Regierer, Rebecca Hasseli, Martin Schäfer, Bimba F. Hoyer, Andreas Krause, Hanns-Martin Lorenz, Alexander Pfeil, Jutta Richter, Tim Schmeiser, Hendrik Schulze-Koops, Anja Strangfeld, Reinhard E. Voll, Christof Specker, Ulf Mueller-Ladner |
|---|
| E-Jahr: | 2021 |
|---|
| Jahr: | 20 October 2021 |
|---|
| Umfang: | 9 S. |
|---|
| Fussnoten: | Gesehen am 29.01.2022 |
|---|
| Titel Quelle: | Enthalten in: RMD Open |
|---|
| Ort Quelle: | London : BMJ Publishing Group, 2015 |
|---|
| Jahr Quelle: | 2021 |
|---|
| Band/Heft Quelle: | 7(2021), 3, Artikel-ID e001896, Seite 1-9 |
|---|
| ISSN Quelle: | 2056-5933 |
|---|
| Abstract: | Introduction Several risk factors for severe COVID-19 specific for patients with inflammatory rheumatic and musculoskeletal diseases (RMDs) have been identified so far. Evidence regarding the influence of different RMD treatments on outcomes of SARS-CoV-2 infection is still poor. - Methods Data from the German COVID-19-RMD registry collected between 30 March 2020 and 9 April 2021 were analysed. Ordinal outcome of COVID-19 severity was defined: (1) not hospitalised, (2) hospitalised/not invasively ventilated and (3) invasively ventilated/deceased. Independent associations between demographic and disease features and outcome of COVID-19 were estimated by multivariable ordinal logistic regression using proportional odds model. - Results 2274 patients were included. 83 (3.6%) patients died. Age, male sex, cardiovascular disease, hypertension, chronic lung diseases and chronic kidney disease were independently associated with worse outcome of SARS-CoV-2 infection. Compared with rheumatoid arthritis, patients with psoriatic arthritis showed a better outcome. Disease activity and glucocorticoids were associated with worse outcome. Compared with methotrexate (MTX), TNF inhibitors (TNFi) showed a significant association with better outcome of SARS-CoV-2 infection (OR 0.6, 95% CI0.4 to 0.9). Immunosuppressants (mycophenolate mofetil, azathioprine, cyclophosphamide and ciclosporin) (OR 2.2, 95% CI 1.3 to 3.9), Janus kinase inhibitor (JAKi) (OR 1.8, 95% CI 1.1 to 2.7) and rituximab (OR 5.4, 95% CI 3.3 to 8.8) were independently associated with worse outcome. - Conclusion General risk factors for severity of COVID-19 play a similar role in patients with RMDs as in the normal population. Influence of disease activity on COVID-19 outcome is of great importance as patients with high disease activity—even without glucocorticoids—have a worse outcome. Patients on TNFi show a better outcome of SARS-CoV-2 infection than patients on MTX. Immunosuppressants, rituximab and JAKi are associated with more severe course. |
|---|
| DOI: | doi:10.1136/rmdopen-2021-001896 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1136/rmdopen-2021-001896 |
|---|
| | Volltext: https://rmdopen.bmj.com/content/7/3/e001896 |
|---|
| | DOI: https://doi.org/10.1136/rmdopen-2021-001896 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | antirheumatic agents |
|---|
| | COVID-19 |
|---|
| | glucocorticoids |
|---|
| K10plus-PPN: | 1787760847 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD / Regierer, Anne C. [VerfasserIn]; 20 October 2021 (Online-Ressource)
Zurück zur Trefferübersicht und Suche
